← Back to Search

Antihypertensive

Reducing Blood Pressure Medication for High Blood Pressure in Frail Elderly (OptimizeBP Trial)

N/A
Waitlist Available
Led By Roni Kraut
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
≥2 diagnoses (dx) of hypertension from either a community practitioner or/and from a hospital admission
on ≥1 oral antihypertensive medication
Timeline
Screening 3 weeks
Treatment Varies
Follow Up ≥6-weeks post-randomisation through study completion (estimated to be 4 years, trial will continue until 247 participants have experienced the primary outcome event)
Awards & highlights

OptimizeBP Trial Summary

This trial is testing whether it's beneficial to reduce blood pressure medication in frail older adults with systolic blood pressure lower than 135 mmHg. The primary outcome is all-cause mortality.

Who is the study for?
This trial is for long-term care residents who are frail, have high blood pressure, and are on at least one oral antihypertensive medication with an average systolic BP below 135 mmHg. They must have been diagnosed with hypertension at least twice. Those on certain heart medications or with specific heart conditions cannot participate.Check my eligibility
What is being tested?
The study tests if reducing blood pressure medication (deprescribing) in frail older adults leads to better health outcomes compared to usual care. The goal is to adjust their medication until their systolic blood pressure is around 140 mmHg, while monitoring mortality rates and other health factors.See study design
What are the potential side effects?
Potential side effects from adjusting antihypertensive medications may include changes in blood pressure that could affect the risk of falls or cognitive impairment, as well as possible impacts on hospitalization rates and quality of life.

OptimizeBP Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with high blood pressure at least twice.
Select...
I am taking at least one pill for high blood pressure.

OptimizeBP Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~≥6-weeks post-randomisation through study completion (estimated to be 4 years, trial will continue until 247 participants have experienced the primary outcome event)
This trial's timeline: 3 weeks for screening, Varies for treatment, and ≥6-weeks post-randomisation through study completion (estimated to be 4 years, trial will continue until 247 participants have experienced the primary outcome event) for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
All-Cause Mortality
Secondary outcome measures
Acute Care Costs
All-Cause Unplanned Hospitalization
Composite of All-Cause Mortality or All-Cause Unplanned Hospitalization
+10 more
Other outcome measures
Average Systolic Blood Pressure and Average Diastolic Blood Pressure
Number of Antihypertensive Medications with ≥25%, ≥50%, and 100% Reduction from Baseline in Dosage Dispensed
Number of Discrete Antihypertensive Medications Used in the Last 15 days (baseline, 3- and 6-months post-randomisation)
+3 more

OptimizeBP Trial Design

2Treatment groups
Experimental Treatment
Active Control
Group I: Deprescribing groupExperimental Treatment1 Intervention
The facility pharmacist will actively deprescribe antihypertensive medication of residents in this group.
Group II: Usual care groupActive Control1 Intervention
The facility pharmacist and the attending physician will provide usual care to residents in this group, and this includes quarterly medication reviews.

Find a Location

Who is running the clinical trial?

University of AlbertaLead Sponsor
883 Previous Clinical Trials
392,759 Total Patients Enrolled
Alberta Health servicesOTHER
156 Previous Clinical Trials
647,331 Total Patients Enrolled
Roni KrautPrincipal InvestigatorUniversity of Alberta

Media Library

Antihypertensive medication (Antihypertensive) Clinical Trial Eligibility Overview. Trial Name: NCT05047731 — N/A
High Blood Pressure Research Study Groups: Deprescribing group, Usual care group
High Blood Pressure Clinical Trial 2023: Antihypertensive medication Highlights & Side Effects. Trial Name: NCT05047731 — N/A
Antihypertensive medication (Antihypertensive) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05047731 — N/A

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are individuals currently being accepted for participation in this trial?

"The clinicaltrials.gov website indicates that this research project is not presently seeking participants; the trial was first published on September 20th, 2021 and last modified on October 14th, 2022. Although recruitment for this particular study has temporarily paused, there are 890 other trials currently welcoming volunteers."

Answered by AI
~150 spots leftby Jun 2025